Last reviewed 2026-04-20 · How we verify

Bronquimucil (BROVANEXINE)

Phase 2 active Small molecule

Bronquimucil (generic name: BROVANEXINE) is a brovanexine drug. It is currently in Phase 2 development.

Bronquimucil (BROVANEXINE) is a small molecule drug that works by interacting with a specific target in the body, but its exact mechanism of action is unknown.

Bronquimucil (BROVANEXINE) is a small molecule drug of the brovanexine class, but specific details about its development, approval, and commercial status are not available. Its target and mechanism of action are unknown. As a result, there is limited information available about its approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to understand the safety and efficacy of this drug. Its commercial status, including whether it is patented or off-patent, is also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BROVANEXINE
Drug class	brovanexine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, we don't know exactly how Bronquimucil (BROVANEXINE) works, but it's thought to target a specific area in the body to produce its effects. More research is needed to understand how it interacts with the body's cells and systems. This lack of information makes it difficult to predict how the drug will affect different people.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bronquimucil CI brief — competitive landscape report
Bronquimucil updates RSS · CI watch RSS

Frequently asked questions about Bronquimucil

What is Bronquimucil?

Bronquimucil (BROVANEXINE) is a brovanexine drug.

How does Bronquimucil work?

Bronquimucil (BROVANEXINE) is a small molecule drug that works by interacting with a specific target in the body, but its exact mechanism of action is unknown.

What is the generic name of Bronquimucil?

BROVANEXINE is the generic (nonproprietary) name of Bronquimucil.

What drug class is Bronquimucil in?

Bronquimucil belongs to the brovanexine class. See all brovanexine drugs at /class/brovanexine.

What development phase is Bronquimucil in?

Bronquimucil is in Phase 2.

Drug class: All brovanexine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing